Drug Profile


Alternative Names: BCH 3963; LEF; LEF 576; SPD 759

Latest Information Update: 25 Jun 2002

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 20 Sep 2001 AstraZeneca discontinued development of frakefamide with rights transferred back to Shire Pharmaceuticals
  • 31 Jul 2001 AstraZeneca offers the rights for frakefamide back to Shire Pharmaceuticals
  • 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top